Clinical Trial

Marshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation

Study acronym: MARVEL-PAF
Recruiting
View on ClinicalTrials.gov →
Summary
The Marvel-PAF trial is an investigator initiated, multi-center, open-label, randomized trial, which aims to compare the effectiveness of vein of Marshall in addition to pulmonary vein isolation using pulsed field ablation in the treatment of paroxysmal atrial fibrillation. The primary endpoint is any atrial arrhythmias lasting ≥30s without AAD during 12 months after procedure excluding the 2-months blanking period.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2025-08-02
Trial Details
NCT Number NCT07095959
Lead Sponsor Beijing Anzhen Hospital
Conditions Atrial Fibrillation (AF)
Enrollment 340 participants
Start Date 2025-07-31
Primary Completion 2027-07-10 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-07